E-LIB Suche - Ergebnisse für: Powles, T.

1

Integrative Analyses of Tumor and Peripheral Biomarkers in ..:

Choueiri, TK ; Donahue, AC ; Braun, DA...
734682. , 2024

2

Prognostic significance of absolute lymphocyte count in pat..:

Takemura, K ; Yuasa, T ; Lemelin, A...
https://pure.au.dk/portal/en/publications/3cf57fe9-e8f4-477e-b806-a6a7b47208a2. , 2024

Link: https://pure.au.dk/porta..

3

Nivolumab plus cabozantinib versus sunitinib for first-line..:

Powles, T ; Burotto, M ; Escudier, B...
Powles , T , Burotto , M , Escudier , B , Apolo , A B , Bourlon , M T , Shah , A Y , Suárez , C , Porta , C , Barrios , C H , Richardet , M , Gurney , H , Kessler , E R , Tomita , Y , Bedke , J , George , S , Scheffold , C , Wang , P , Fedorov , V , Motzer , R J & Choueiri , T K 2024 , ' Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma : extended follow-up from the phase III randomised CheckMate 9ER trial ' , ESMO Open , vol. 9 , no. 5 , 102994 , pp. 1-11 . https://doi.org/10.1016/j.esmoop.2024.102994. , 2024

Link: https://researchers.mq.e..

4

Prognostic significance of absolute lymphocyte count in pat..:

Takemura, K ; Yuasa, T ; Lemelin, A...
https://portal.findresearcher.sdu.dk/da/publications/967ee475-632a-4374-b553-aeec2498ded5. , 2024

Link: https://portal.findresea..

5

Benchmarking Maintenance Therapy Survival in First-Line Pla..:

Galsky MD ; Wirtz HS ; Bloudek B...
https://www.dovepress.com/benchmarking-maintenance-therapy-survival-in-first-line-platinum-based-peer-reviewed-fulltext-article-CLEP. , 2023

Link: https://doaj.org/article..

6

Efficacy and safety of pembrolizumab in metastatic urotheli..:

Balar, A. V ; Castellano, D. E ; Grivas, P...
https://pure.eur.nl/en/publications/13c8979f-cdd3-4141-9be7-a8246545dec9. , 2023

Link: https://pure.eur.nl/en/p..

7

A randomized, double-blind, biomarker-selected, phase II cl..:

Crabb, S.J ; Hussain, S ; Soulis, E...
https://eprints.whiterose.ac.uk/199539/1/A%20Randomized,%20Double-Blind,%20Biomarker-Selected,%20Phase%20II%20Clinical%20Trial%20of%20Maintenance%20Poly%20ADP-Ribose%20Polymerase%20Inhibition.pdf. , 2023

Link: https://eprints.whiteros..

8

Efficacy and safety of pembrolizumab in metastatic urotheli..:

Balar, A. V ; Castellano, D. E ; Grivas, P...
https://pure.eur.nl/en/publications/13c8979f-cdd3-4141-9be7-a8246545dec9. , 2023

Link: https://pure.eur.nl/en/p..

9

The potential of using circulating tumour cells and their g..:

Davies, CR ; Guo, T ; Burke, E...
Frontiers in Oncology. , 2023

Link: https://qmro.qmul.ac.uk/..

10

Avelumab Plus Axitinib as First-Line Therapy for Advanced R..:

Larkin, J ; Oya, M ; Martignoni, M...
6961606. , 2023

Link: https://repository.icr.a..

11

Improved Disease-Free Survival With Adjuvant Chemotherapy A..:

Birtle, AJ ; Jones, R ; Chester, J...
Journal of Clinical Oncology,. , 2023

Link: https://repository.icr.a..

12

Temporary treatment cessation versus continuation of first-..:

Brown, JE ; Royle, K-L ; Gregory, W...
https://eprints.whiterose.ac.uk/196442/12/Temporary%20treatment%20cessation%20versus%20continuation%20of.pdf. , 2023

Link: https://eprints.whiteros..

13

Standard versus modified ipilimumab, in combination with ni..:

Vasudev, N.S ; Ainsworth, G ; Brown, S...
https://eprints.whiterose.ac.uk/205491/2/vasudev-et-al-2023-standard-versus-modified-ipilimumab-in-combination-with-nivolumab-in-advanced-renal-cell-carcinoma-a.pdf. , 2023

Link: https://eprints.whiteros..

14

A Randomized, Double-Blind, Biomarker-Selected, Phase II Cl..:

Crabb, SJ ; Hussain, S ; Soulis, E...
https://discovery.ucl.ac.uk/id/eprint/10170742/1/A%20Randomized,%20Double-Blind,%20Biomarker-Selected,%20Phase%20II%20Clinical%20Trial%20of%20Maintenance%20Poly%20ADP-Ribose%20Polymerase%20Inhibition.pdf. , 2023

Link: https://discovery.ucl.ac..

15

Safety and efficacy of cobimetinib plus atezolizumab in pat..:

Sherman, E ; Lee, JL ; Debruyne, PR...
100877. , 2023

Link: https://repository.icr.a..